## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.3% below STRENGTH zone (3.0-6.0%); PEG 3.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($554.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. ISRG Pre-Market (29 Dec 2025): Innovations in AI Surgical Systems**
- Source: Meyka | 20251229T151826 | Bullish | Relevance: 100%
- Intuitive Surgical, Inc. (NASDAQ: ISRG) is leveraging AI technologies to improve precision and outcomes in minimally invasive surgeries with its da Vinci and Ion systems. The company has shown robust growth with a 34.13% increase in stock price over the last month, a P/E ratio of 76.43, and reported revenue of USD 2.24 billion last quarter. Meyka AI rates ISRG with an 'A' grade and a 'BUY' recommendation, forecasting potential growth to USD 607.53 in the next month and USD 757.26 in five years.

**2. Annex Advisory Services LLC Has $27.30 Million Holdings in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251229T084729 | Bullish | Relevance: 100%
- Annex Advisory Services LLC increased its stake in Intuitive Surgical, Inc. by 7.8% during the third quarter, bringing their total holdings to 61,051 shares valued at approximately $27.30 million. Intuitive Surgical recently surpassed earnings estimates with an EPS of $2.40 and revenue of $2.51 billion, showing a 22.9% year-over-year revenue increase. Analysts maintain a "Moderate Buy" consensus rating for ISRG, with an average price target of $611.08, despite recent insider share sales.

**3. Sapient Capital LLC Trims Stake in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251228T121921 | Somewhat-Bullish | Relevance: 100%
- Sapient Capital LLC reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 53.3% in the third quarter of 2025, selling 51,663 shares and retaining 45,314 shares valued at $19.92 million. The medical equipment provider reported strong Q3 earnings, surpassing analyst expectations with an EPS of $2.40 and revenue of $2.51 billion. Despite the institutional selling, insiders hold 0.70% of the stock, while institutions own a substantial 83.64%.

**4. Intuitive Surgical, Inc. $ISRG is Valicenti Advisory Services Inc.'s 10th Largest Position**
- Source: MarketBeat | 20251228T120531 | Bullish | Relevance: 100%
- Valicenti Advisory Services Inc. increased its stake in Intuitive Surgical, Inc. by 8.5% in the third quarter, making it their 10th largest holding. Other institutional investors like Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, Norges Bank, and Invesco Ltd. also adjusted their positions. Insiders such as Myriam Curet and Gary S. Guthart have sold shares, while analysts maintain a "Moderate Buy" consensus with an average target price of $611.08.

**5. Apollon Wealth Management LLC Decreases Stake in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251228T082625 | Somewhat-Bullish | Relevance: 100%
- Apollon Wealth Management LLC reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.2% in the third quarter, now holding 22,837 shares valued at $10.21 million. This comes as company insiders have been net sellers, offloading over 114,000 shares worth approximately $63.53 million in the past 90 days. Despite the insider selling, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $611.08 for ISRG.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.55 signals overvaluation risk, limited margin of safety. Forward P/E 59.0x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $206.3B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.55 |
| Forward P/E | 59.0 |
| Current P/E | 66.6 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.0% to 0.3% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.7pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.26% (CS: 72) | Neutral |
| RSI_14 | 59.1 | Neutral |
| MACD Histogram | 0.45 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.128x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $575.40
- **Stop Loss:** $554.34 (3.7% risk)
- **Target:** $596.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $37,401.00
- **Portfolio %:** 37.40%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*